PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
39.51
-1.14 (-2.80%)
May 6, 2025, 12:34 PM EDT - Market open
PTC Therapeutics Revenue
In the year 2024, PTC Therapeutics had annual revenue of $806.78M, down -13.97%. PTC Therapeutics had revenue of $213.17M in the quarter ending December 31, 2024, a decrease of -30.58%.
Revenue (ttm)
$806.78M
Revenue Growth
-13.97%
P/S Ratio
3.87
Revenue / Employee
$859,191
Employees
939
Market Cap
3.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
PTCT News
- 19 hours ago - Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - Benzinga
- 1 day ago - PTC518 PIVOT-HD Study Achieves Primary Endpoint - PRNewsWire
- 4 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 11 days ago - PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - PRNewsWire
- 12 days ago - PTC Therapeutics to Participate at Upcoming Investor Conferences - PRNewsWire
- 19 days ago - PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results - PRNewsWire
- 5 weeks ago - PTC Therapeutics Shares Fall After EU Drops Translarna Authorization - Market Watch
- 5 weeks ago - PTC Therapeutics says European Commission will remove muscle disorder drug - Reuters